Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$97.63 +1.38%

+$1.21 today

Market cap
$9.27B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 0.63M

Average 1.17M

Returns on capital

Spyre Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-21.7%

avg -78.6%

ROIC

-29.1%

avg -66.7%

ROA

-20.0%

avg -58.4%

Analysis

ROA is currently the strongest return metric at -20.0% versus its period average of -58.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Cameron Turtle DPHIL

Chief Executive Officer & DirectorUSD 1.15M36——

Sheldon Sloan

Chief Medical OfficerUSD 778.56K670<0.01%

Scott L. Burrows

Chief Financial OfficerUSD 758.8K4979.76K0.13%

Heidy Abreu King-Jones

Chief Legal Officer & Corporate SecretaryUSD 758.8K43——

Eric McIntyre

Senior Vice President of Finance & Investor Relations————

James Myers

Senior Vice President of Quality & Compliance————

Melissa Cooper

Senior Vice President of People————

Janet Gunzner-Toste

Senior Vice President of Operations————

Justin LaFountaine

Senior Vice President of Corporate Development————

Brian Connolly

Chief Technical Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 1, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

94

$441.93M

Net Transaction Value

−$441.93M

Net selling

Most Active

Turtle Cameron

38 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 1, 26

King-Jones Heidy

Direct

Sell$1.5M
Oct 1, 26

Burrows Scott L

Direct

Sell$135.4K
Oct 1, 26

Burrows Scott L

Direct

Sell$193K
Oct 1, 26

Burrows Scott L

Direct

Sell$285.4K
Oct 1, 26

Burrows Scott L

Direct

Sell$21.4K
Oct 1, 26

King-Jones Heidy

Direct

Sell$35.7K
Oct 1, 26

King-Jones Heidy

Direct

Sell$660.3K
Oct 1, 26

King-Jones Heidy

Direct

Sell$194.7K
Oct 1, 26

King-Jones Heidy

Direct

Sell$243K
Oct 1, 26

Turtle Cameron

Direct

Sell$53.5K

1–10 of 94

Summary

Insiders reported 0 buys worth $0.00 and 94 sells worth $441.93M over the last 12 months. That adds up to net selling of $441.93M. Turtle Cameron was the most active insider with 38 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
N/A4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Spyre Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about SYRE's management, answered from reported figures.

Who manages SYRE?

Spyre Therapeutics, Inc. (SYRE) lists 10 active executives. The top listed executive is Eric McIntyre, Senior Vice President of Finance & Investor Relations.

Are SYRE insiders buying or selling?

Recent insider activity shows net selling of $369.19M.